Agenus (AGEN) vs Editas Medicine (EDIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Agenus (AGEN) has outperformed Editas Medicine (EDIT) over the past year, gaining 41.5% versus a loss of 32.2%. Over five years, AGEN leads with a -90.6% price change compared with -94.9% for EDIT. Agenus is the larger company by market cap ($270.1 million vs $253.1 million), about 1.1 times the size, while Editas Medicine is growing revenue faster (+25.4% vs +10.4%).
Agenus converts more of its revenue into profit, with a net margin of -2.7% versus -395.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | EDIT |
|---|---|---|
| Share price | $5.97 | $1.64 |
| Market cap | $270.12M | $253.12M |
| 1-day change | -2.77% | -4.09% |
| YTD return | +90.13% | -20.00% |
| 1-year return | +41.47% | -32.23% |
| 5-year return | -90.58% | -94.93% |
| P/E ratio (TTM) | 25.96 | — |
| EPS (TTM) | $0.23 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $114.20M | $40.52M |
| Revenue growth (YoY) | +10.37% | +25.39% |
| Net income (latest FY) | $-3.08M | $-160.06M |
| Gross margin | 99.11% | — |
| Operating margin | -17.66% | -394.89% |
| Net margin | -2.70% | -395.01% |
| 52-week high | $10.31 | $3.94 |
| 52-week low | $2.71 | $1.63 |
| Distance from 52-week high | -42.10% | -58.38% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +352.26% | +271.95% |
| Average volume | 905.17K | 2.63M |
| Shares outstanding | 45.25M | 154.34M |
| Employees | 81 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGEN has outperformed EDIT by 73.7 percentage points over the past year.
- Agenus is more profitable, keeping -2.7 cents of every revenue dollar as net income versus -395.0 cents for Editas Medicine.
- Editas Medicine grew revenue faster in its latest fiscal year (+25.39% vs +10.37%).
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
AGEN vs EDIT FAQ
Which is bigger, Agenus or Editas Medicine?
Agenus (AGEN) is larger, with a market capitalization of $270.12M compared with $253.12M for Editas Medicine (EDIT).
Which stock has performed better over the past year, AGEN or EDIT?
AGEN returned +41.47% over the past 12 months, compared with -32.23% for EDIT (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and Editas Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.